I'm LongbridgeAI, I can summarize articles.Clover Biopharmaceuticals (HK:2197) expects a net profit of RMB957m-RMB1.204b for H1 2026, reversing last year's loss, primarily due to a one-off gain from a Gavi settlement. Excluding this non-recurring item, the company will still report a net loss driven by high R&D costs and limited revenue. Management warns that figures are unaudited preliminary data subject to change, urging investors to await official results in August 2026.
Clover Biopharmaceuticals Ltd. ( (HK:2197) ) just unveiled an update.
Clover Biopharmaceuticals has issued a positive profit alert, indicating it expects to report a net profit of about RMB957 million to RMB1.204 billion for the first half of 2026, reversing a loss of roughly RMB101.3 million a year earlier. The swing to profit is mainly due to a large, non-recurring accounting gain linked to a settlement agreement with Gavi reached in March 2026.
The company stressed that, excluding this one-off gain, it will still post a net loss for the period, driven by ongoing R&D spending and a lack of significant operating revenue. Management cautioned that the figures are based on unaudited preliminary data and may change, urging investors to await the interim results expected in August 2026 and to exercise caution when trading the company’s shares.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. is a biotechnology company focused on developing innovative biopharmaceutical products, with a business heavily driven by research and development activities. The company currently has limited operating revenue, reflecting its emphasis on pipeline development rather than commercialized products.
Average Trading Volume: 4,292,890
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.92B